Avid Bioservices Inc (CDMO)

[cjgaddy]

2-17-16/BiotechStocks: 4 Stocks to Consider for Biotech Turnaround. Don't know anything about BiotechStocks, but a straightforward overview, 'tho no mention of the 3 new 2015-16 collabs, MSKCC, AstraZeneca, and NCCN...

2-17-16/BiotechStocks: 4 Stocks to Consider for Biotech Turnaround
http://finance.yahoo.com/news/4-stocks-consider-biotech-turnaround-165500882.html
...Curis, Inc. (CRIS $1.50), Del Mar Pharm. (DMPI $.78), Immune Design (IMDZ $10.73)...
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM)
Peregrine's lead candidate is bavituximab, which is a chimeric monoclonal antibody. Essentially, the drug binds to receptors on the surface of cancerous cells and signals the immune system to come and attack endothelial cells. Endothelial cells are cells that line blood vessels, and so through inducing this attack, bavituximab aims to cut off the blood supply to a tumor and halt its growth. Data from a Ph. II trial in lung cancer [6-3-13/ASCO’13: Final Data Ph.II 2L/NSCLC http://tinyurl.com/my8qxw7 “…60% improvement in MOS: Bavi/3mg=11.7mos. vs. 7.3mos. for CTL-arm(combined Bavi/1mg + DoxyOnly arms), HR=.662, P=.113” ] demonstrated superiority to docetaxel, a multi billion dollar blockbuster currently marketed by Sanofi (NYSE: SNY) - and Peregrine is currently running a large Ph. III of 600 enrolled patients in the same indication. The trial is again pitching bavituximab against Docetaxel, with a 3rd placebo arm thrown in. If the drug can replicate the Ph. II data in this trial (called SUNRISE - all details here: https://www.clinicaltrials.gov/ct2/show/NCT01999673 ), Peregrine could have a real blockbuster on its hands. The trial is expected to complete in December this year, so again look for any interim updates to provide upside catalysts, and end of the year top-line efficacy to form the basis of an early 2017 NDA submission.
Source: Biotech Stocks ( http://www.BiotechStocks.com )
Direct link: http://biotechstocks.com/4-stocks-to-consider-for-a-biotech-turnaround